)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Laboratorios Farmaceuticos Rovi
Laboratorios Farmaceuticos Rovi (ROVI) investor relations material
Laboratorios Farmaceuticos Rovi Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary5 Nov, 2026
Executive summary
9M 2026 total revenue rose 19% to €633.7 Mn; operating revenue increased 16% to €610.2 Mn, led by CDMO growth.
Net profit increased 67% to €162.8 Mn; reported EBITDA rose 52% to €226.6 Mn, including a €62.4 Mn non-recurring Phoenix bargain purchase gain.
Financial highlights
Gross profit increased 26% to €443.7 Mn; gross margin expanded 5.7 pp to 72.7%, including CDTI grant income.
EBITDA excluding the €62.4 Mn bargain purchase gain was €164.3 Mn, up 10%, with a 26.9% margin.
EBIT rose 56% to €198.7 Mn; net profit rose 67% to €162.8 Mn.
SG&A increased 24% to €221.2 Mn, reflecting Phoenix integration, additional CDMO staff and non-recurring costs; R&D expenses rose 136% to €58.4 Mn, mainly due to Letrozole SIE Phase III preparation and launch.
Net cash from operating activities was €111.0 Mn versus €101.4 Mn; free cash flow was €61.9 Mn versus €63.3 Mn.
Outlook and guidance
2026 operating revenue guidance upgraded to mid-to-high-single-digit growth vs. 2025, from low-to-mid-single-digit growth, on CDMO momentum and expected bemiparin volumes.
2026 LMWH sales are expected to decline by a mid-single-digit percentage; bemiparin sales are expected to grow by a low-single-digit percentage.
2026 SG&A guidance remains mid-to-high-single-digit growth vs. 2025, excluding Phoenix expenses; 2027 guidance is expected with FY 2026 results in February 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Laboratorios Farmaceuticos Rovi
- Revenue and profit surged, driven by CDMO and Okedi® growth plus a major one-time gain.ROVI
Q2 2026 - Stable Q1 revenue and margin gains, but net profit and heparin sales declined sharply.ROVIQ1 2026
- Specialty pharma growth and strategic deals offset CDMO decline, boosting profit and cash flow.ROVIQ4 2025
- Revenue and profit surged on strong CMO growth, new launches, and expanded Moderna partnership.ROVIQ2 2022
- Phoenix site acquisition secures BMS contract, expands US capacity, and strengthens global CDMO position.ROVIInvestor Update
- Revenue down 5%, gross margin up 4.7 pp, Okedi® up 126%, net profit down 4%, outlook cautious.ROVIQ3 2024
- H1 2024 revenue fell 14%, net profit dropped 33%, but gross margin rose to 59.4%.ROVIQ2 2024
- Revenue to rise 1.5x–1.8x by 2030, doubling CDMO sales and expanding specialty pharma.ROVICMD 2025
- Revenue fell 7.9% as CDMO sales dropped, but specialty pharma and Okedi drove growth.ROVIQ4 2024
Next Laboratorios Farmaceuticos Rovi earnings date
Q4 202624 Feb, 2027
Laboratorios Farmaceuticos Rovi
Next Laboratorios Farmaceuticos Rovi earnings date
Q4 202624 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Laboratorios Farmacéuticos Rovi S.A. is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of proprietary and in-licensed drugs. It serves therapeutic areas including cardiovascular, hematology, and endocrinology. The company is headquartered in Madrid, Spain, and its shares are listed on the BME.